Skip to main content
. 2020 Dec 1;11(48):4504–4520. doi: 10.18632/oncotarget.27830

Figure 3. Efficacy and selectivity of preventive and therapeutic HIF-1α and HIF-2α ASO treatment in DEN-induced HCC mice.

Figure 3

HCC was induced by weekly intraperitoneal DEN injection for 25 weeks. Control mice received weekly intraperitoneal 0.9% NaCl injection. DEN-treated mice were intraperitoneally injected with 20 mg/kg HIF-1α ASO, HIF-2α ASO or scrambled ASO twice per week, in either a preventive or a therapeutic setting. Control mice received scrambled ASO for the same duration of the experiment. Hepatic mRNA expression of the HIFα isoforms following preventive and therapeutic treatment is shown. The upper and lower dashed lines represent log2-transformed mean ± SD of the control mice. Bars represent log2-transformed mean ± SD of different treatment groups of DEN-treated mice, relative to the log2-transformed mean of the control mice (n = 7–9 per treatment group). * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001.